Home > Signaling Pathways>Apoptosis>Apoptosis>Evofosfamide (TH-302)
Evofosfamide (TH-302)

This product is for research use only, not for human use. We do not sell to patients.

Evofosfamide (TH-302)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
100mg$845Check With Us
250mg$1550Check With Us
500mg$2325Check With Us

Cat #: V1875 CAS #: 918633-87-1 Purity ≥ 98%

Description: Evofosfamide (TH-302) is potent and selective hypoxia-activated prodrug targeting hypoxic regions of solid tumors with IC50 of 19 nM, demonstrates 270-fold enhanced cytotoxicity under hypoxia versus their potency under aerobic conditions, stable to cytochrome P450 metabolism.

References: Meng F, et al. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21;15:422.

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)449.04
Molecular FormulaC9H16Br2N5O4P
CAS No.918633-87-1
Storage-20℃ for 3 years in powder formr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: 90 mg/mL (200.4 mM)r
Water: 10 mg/mL (22.3 mM)r
Ethanol: 90 mg/mL (200.4 mM)
Solubility In Vivo30% Propylene glycol, 5% Tween 80, 65% D5W: 30 mg/mL
SMILES CodeO=P(NCCBr)(NCCBr)OCC1=CN=C([N+]([O-])=O)N1C
SynonymsTH302; TH 302; TH-302
ProtocolIn VitroEvofosfamide (TH-302) induces γH2AX and apoptosis. Evofosfamide displays hypoxia-selective and concentration-dependent cytotoxic activity that is comparable in both p53-proficient and -deficient cells. Treatment with Evofosfamide (TH-302) alone causes an accumulation of G2/M cells. Inhibition of Chk1 by PF47736 in cells treated with Evofosfamide reduces Evofosfamide (TH-302)-mediated G2/M arrest under both normoxia and hypoxia.
In VivoEvofosfamide (TH-302) is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. The mean values of normalized Ktrans decrease 69.2% for Evofosfamide (TH-302)-treated mice in Hs766t tumors, decrease 46.1% for Mia PaCa-2 tumors and increase 4.9% in SU.86.86 tumors. Both changes for Hs766t and Mia PaCa-2 treatment groups are statistically significant (P<0.01) when compare to their own control group.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM2.2270 mL11.1349 mL22.2697 mL44.5395 mL
5mM0.4454 mL2.2270 mL4.4539 mL8.9079 mL
10mM0.2227 mL1.1135 mL2.2270 mL4.4539 mL
20mM0.1113 mL0.5567 mL1.1135 mL2.2270 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.